CRISPR Therapeutics And Sirius Therapeutics Announce First Patient Dosed In Phase 2 Clinical Trial Of SRSD107, Factor XI siRNA For Prevention Of VTE In Patients Undergoing TKA

Author: Benzinga Newsdesk | September 22, 2025 08:34am

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a clinical stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, today announced that the first patient has been dosed in a Phase 2 clinical trial of SRSD107, a next-generation, long-acting Factor XI (FXI) siRNA for the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA). SRSD107 is being co-developed by CRISPR Therapeutics and Sirius Therapeutics as part of a strategic collaboration to advance innovative treatments for cardiovascular and clotting-related diseases.

Posted In: CRSP